search
Back to results

Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae (FMT)

Primary Purpose

Carbapenem-Resistant Enterobacteriaceae Infection, Fecal Microbiota Transplantation

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Fecal microbiota transplant
Sham fecal microbiota transplant
Sponsored by
The University of Hong Kong
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Carbapenem-Resistant Enterobacteriaceae Infection focused on measuring FMT, CRE

Eligibility Criteria

18 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: All adult patients aged 18 or above admitted to the medical ward of Queen Mary Hospital, the teaching hospital of the University of Hong Kong Rectal swabs or stool specimens showing the presence of CRE Positive CRE specimen within one week of commencement Exclusion Criteria: Pregnancy Severe immunodeficiency (e.g. advanced human immunodeficiency virus infection (CD4 lymphocyte count ≤200/mm3), myelosuppressive chemotherapy) Significant neutropenia (absolute neutrophil count ≤1.0 x 109/L) Recent antibiotic use within 30 days prior to consent Contraindications for retention enema (intestinal obstruction, ileus and gut perforation).

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Placebo Comparator

    Arm Label

    Fecal microbiota transplant

    Sham fecal microbiota transplant

    Arm Description

    This group's subject will receive an infusion of 125mL fecal suspension via enema.

    This group's subject will receive 125mL placebo enema comprised of normal saline with 15% glycerol and brown food colouring 204 (Americolorcorp) as a sham procedure.

    Outcomes

    Primary Outcome Measures

    CRE clearance rate
    CRE clearance rate via enema

    Secondary Outcome Measures

    CRE clearance rate
    CRE clearance rate post-FMT
    All-cause mortality
    All-cause mortality post-FMT

    Full Information

    First Posted
    July 31, 2023
    Last Updated
    August 9, 2023
    Sponsor
    The University of Hong Kong
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05981430
    Brief Title
    Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae
    Acronym
    FMT
    Official Title
    Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae: a Double Blind Randomized Controlled Trial
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    August 20, 2023 (Anticipated)
    Primary Completion Date
    August 19, 2025 (Anticipated)
    Study Completion Date
    August 19, 2025 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    The University of Hong Kong

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No

    5. Study Description

    Brief Summary
    The emergence of multidrug-resistant organisms (MDROs) has become one of the major threats to the healthcare system in Hong Kong in recent years. The situation is particularly worrisome for carbapenem-resistant Enterobacteriaceae (CRE). Taking Queen Mary Hospital as an example, the number of CRE cases has surged from 24 in year 2014 to 625 in year 2021. The case burden in Hong Kong is therefore substantial when all 43 public hospitals and institutions in Hong Kong are considered. With the widespread use of broad-spectrum antibiotics and active case screening, the number of CRE cases is expected to further increase in an exponential manner. Given that colonization with MDROs is due to gut dysbiosis from antibiotic use, a normal intestinal microbiota is apparently crucial in protecting hosts from colonization with MDROs including CRE. Fecal microbiota transplantation (FMT), which involves the infusion of stool from a healthy donor to the gastrointestinal (GI) tract of a recipient, has gained popularity in recent years to restore colonic microbial diversity in various diseases associated with gut dysbiosis, e.g. Clostridium difficile (CD) infection, ulcerative colitis and even metabolic diseases. The investigators aim to conduct a double-blind randomized controlled trial to evaluate the benefit of FMT via lower GI delivery (enema) on CRE clearance.
    Detailed Description
    CRE colonization is associated with a 16.5% risk of infection with a 10% mortality rate. CRE also poses a tremendous strain on the healthcare cost as well as the medical/nursing manpower. The hospital stay is lengthened by two-fold for CRE-infected cases compared with non-infected cases. CRE carriers frequently have to stay in acute hospitals for extended periods of time after settling their acute illnesses, both because of the logistic infeasibility of them being transferred to rehabilitation units or nursing homes, which are devoid of isolation rooms. Proactive measures have been implemented in hospitals worldwide to prevent the spread of MDROs, especially to vulnerable individuals. Such measures usually include surveillance culture, contact tracing, isolation of carriers and environmental disinfection. Nevertheless, isolation facilities are not always readily available, particularly in resource-limited regions. In addition, contact isolation may result in various adverse effects on the mental well-being of isolated patients, such as depression, anxiety and anger. Time spent with patients in isolation by healthcare workers is less, with a negative effect on patient safety with an eight-fold increase in the risk of adverse events due to supportive care failure. There has been a growing interest in extending FMT for the decolonization of CRE. However, most of the studies are limited to case reports or case series with small sample sizes (ranging from 10 to 39 patients) as shown by a recent systematic review. The pooled rate of CRE decolonization is promising at 62.1%. However, a randomized controlled trial (RCT) remains the most optimal study design to investigate the true beneficial effect of FMT on CRE decolonization. FMT via enema route has several advantages over upper GI delivery or colonoscopy. First, the administration of fecal suspension via a feeding tube may not be acceptable to some patients. Second, colonoscopy carries complications of gut perforation, aspiration, and cardiopulmonary suppression from the use of sedatives, in particular among frail and elder patients.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Carbapenem-Resistant Enterobacteriaceae Infection, Fecal Microbiota Transplantation
    Keywords
    FMT, CRE

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantCare ProviderInvestigator
    Allocation
    Randomized
    Enrollment
    80 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Fecal microbiota transplant
    Arm Type
    Active Comparator
    Arm Description
    This group's subject will receive an infusion of 125mL fecal suspension via enema.
    Arm Title
    Sham fecal microbiota transplant
    Arm Type
    Placebo Comparator
    Arm Description
    This group's subject will receive 125mL placebo enema comprised of normal saline with 15% glycerol and brown food colouring 204 (Americolorcorp) as a sham procedure.
    Intervention Type
    Biological
    Intervention Name(s)
    Fecal microbiota transplant
    Intervention Description
    Active comparator will receive infusion of 125mL fecal suspension via enema
    Intervention Type
    Biological
    Intervention Name(s)
    Sham fecal microbiota transplant
    Intervention Description
    Placebo comparator will receive 125mL placebo enema comprised of normal saline with 15% glycerol and brown food coloring 204 (Americolorcorp).
    Primary Outcome Measure Information:
    Title
    CRE clearance rate
    Description
    CRE clearance rate via enema
    Time Frame
    1 month post-FMT
    Secondary Outcome Measure Information:
    Title
    CRE clearance rate
    Description
    CRE clearance rate post-FMT
    Time Frame
    1 week, 2 week, 3 month, 6 month and 12 month post-FMT
    Title
    All-cause mortality
    Description
    All-cause mortality post-FMT
    Time Frame
    1 month, 3 month, 6 month and 12 month post-FMT

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    90 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: All adult patients aged 18 or above admitted to the medical ward of Queen Mary Hospital, the teaching hospital of the University of Hong Kong Rectal swabs or stool specimens showing the presence of CRE Positive CRE specimen within one week of commencement Exclusion Criteria: Pregnancy Severe immunodeficiency (e.g. advanced human immunodeficiency virus infection (CD4 lymphocyte count ≤200/mm3), myelosuppressive chemotherapy) Significant neutropenia (absolute neutrophil count ≤1.0 x 109/L) Recent antibiotic use within 30 days prior to consent Contraindications for retention enema (intestinal obstruction, ileus and gut perforation).
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Ka Shing Cheung
    Phone
    22554769
    Email
    cks634@hku.hk
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Ka Shing Cheung
    Organizational Affiliation
    The University of Hong Kong
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    21429622
    Citation
    Backman C, Taylor G, Sales A, Marck PB. An integrative review of infection prevention and control programs for multidrug-resistant organisms in acute care hospitals: a socio-ecological perspective. Am J Infect Control. 2011 Jun;39(5):368-378. doi: 10.1016/j.ajic.2010.07.017. Epub 2011 Mar 23.
    Results Reference
    background
    PubMed Identifier
    28707337
    Citation
    Quraishi MN, Widlak M, Bhala N, Moore D, Price M, Sharma N, Iqbal TH. Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection. Aliment Pharmacol Ther. 2017 Sep;46(5):479-493. doi: 10.1111/apt.14201. Epub 2017 Jul 14.
    Results Reference
    background
    PubMed Identifier
    35461908
    Citation
    Macareno-Castro J, Solano-Salazar A, Dong LT, Mohiuddin M, Espinoza JL. Fecal microbiota transplantation for Carbapenem-Resistant Enterobacteriaceae: A systematic review. J Infect. 2022 Jun;84(6):749-759. doi: 10.1016/j.jinf.2022.04.028. Epub 2022 Apr 21.
    Results Reference
    background

    Learn more about this trial

    Fecal Microbiota Transplantation for Decolonization of Carbapenem-resistant Enterobacteriaceae

    We'll reach out to this number within 24 hrs